256 related articles for article (PubMed ID: 24492291)
1. Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.
Kornberger P; Skerra A
MAbs; 2014; 6(2):354-66. PubMed ID: 24492291
[TBL] [Abstract][Full Text] [Related]
2. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
[TBL] [Abstract][Full Text] [Related]
3. A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
[TBL] [Abstract][Full Text] [Related]
4. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life.
Schlapschy M; Theobald I; Mack H; Schottelius M; Wester HJ; Skerra A
Protein Eng Des Sel; 2007 Jun; 20(6):273-84. PubMed ID: 17595342
[TBL] [Abstract][Full Text] [Related]
5. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
7. Receptor-directed chimeric toxins created by sortase-mediated protein fusion.
McCluskey AJ; Collier RJ
Mol Cancer Ther; 2013 Oct; 12(10):2273-81. PubMed ID: 23945077
[TBL] [Abstract][Full Text] [Related]
8. High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.
Mendler CT; Friedrich L; Laitinen I; Schlapschy M; Schwaiger M; Wester HJ; Skerra A
MAbs; 2015; 7(1):96-109. PubMed ID: 25484039
[TBL] [Abstract][Full Text] [Related]
9. Reduction of non-specific toxicity of immunotoxin by intein mediated reconstitution on target cells.
Wang J; Han L; Chen J; Xie Y; Jiang H; Zhu J
Int Immunopharmacol; 2019 Jan; 66():288-295. PubMed ID: 30502650
[TBL] [Abstract][Full Text] [Related]
10. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
12. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
13. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
Mujoo K; Reisfeld RA; Cheung L; Rosenblum MG
Cancer Immunol Immunother; 1991; 34(3):198-204. PubMed ID: 1756537
[TBL] [Abstract][Full Text] [Related]
14. Comparison of alternative nucleophiles for Sortase A-mediated bioconjugation and application in neuronal cell labelling.
Baer S; Nigro J; Madej MP; Nisbet RM; Suryadinata R; Coia G; Hong LP; Adams TE; Williams CC; Nuttall SD
Org Biomol Chem; 2014 May; 12(17):2675-85. PubMed ID: 24643508
[TBL] [Abstract][Full Text] [Related]
15. Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.
Chen P; Bordeau BM; Zhang Y; Balthasar JP
Mol Cancer Ther; 2022 Oct; 21(10):1573-1582. PubMed ID: 35930739
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
Zhou H; Hittelman WN; Yagita H; Cheung LH; Martin SS; Winkles JA; Rosenblum MG
Cancer Res; 2013 Jul; 73(14):4439-50. PubMed ID: 23722548
[TBL] [Abstract][Full Text] [Related]
17. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
18. Selective formation of covalent protein heterodimers with an unnatural amino acid.
Hutchins BM; Kazane SA; Staflin K; Forsyth JS; Felding-Habermann B; Smider VV; Schultz PG
Chem Biol; 2011 Mar; 18(3):299-303. PubMed ID: 21439474
[TBL] [Abstract][Full Text] [Related]
19. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Deng W; Liu J; Pan H; Li L; Zhou C; Wang X; Shu R; Dong B; Cao D; Li Q; Wang Z
J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
[TBL] [Abstract][Full Text] [Related]
20. Production of anti-cancer immunotoxins in algae: ribosome inactivating proteins as fusion partners.
Tran M; Henry RE; Siefker D; Van C; Newkirk G; Kim J; Bui J; Mayfield SP
Biotechnol Bioeng; 2013 Nov; 110(11):2826-35. PubMed ID: 23719862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
